Cardiogen Biosciences

Palo Alto, United States Founded: 2014 • Age: 12 yrs Acquired By AudentesTherapeutics
AAV gene therapies are developed for rare inherited arrhythmogenic diseases.

About Cardiogen Biosciences

Cardiogen Biosciences is a company based in Palo Alto (United States) founded in 2014 was acquired by AudentesTherapeutics in September 2015.. Cardiogen Biosciences has raised $525.8 thousand across 1 funding round from investors including AudentesTherapeutics. Cardiogen Biosciences operates in a competitive market with competitors including Insitro, BridgeBio, ATAI, Forge Biologics and Spark Therapeutics, among others.

  • Headquarter Palo Alto, United States
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
Operational Areas
Healthcare → Healthcare Products & Supplies
Healthcare → Healthcare Products & Supplies
Healthcare → Biotechnology, Genomics & Life Sciences Research
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $525.8 K (USD)

    in 1 rounds

  • Latest Funding Round
    $525.8 K (USD), Seed

    Nov 06, 2014

  • Investors
  • Employee Count
    Employee Count
  • Acquired by
    AudentesTherapeutics

    (Sep 01, 2015)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of Cardiogen Biosciences

Cardiogen Biosciences has successfully raised a total of $525.8K through 1 strategic funding round. The most recent funding activity was a Seed round of $525.8 thousand completed in November 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 1
  • Last Round Seed — $525,795
  • First Round

    (06 Nov 2014)

  • Investors Count
Date Amount Transaction Name Valuation Lead Investors Investors
Nov, 2014 Amount Seed - Cardiogen Biosciences Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Cardiogen Biosciences

Cardiogen Biosciences has secured backing from 1 investor. Prominent investors backing the company include AudentesTherapeutics. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Investor Description Founded Year Domain Location
Developer of therapeutics to treat rare genetic diseases
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Cardiogen Biosciences

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Cardiogen Biosciences

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Cardiogen Biosciences Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Cardiogen Biosciences

Cardiogen Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insitro, BridgeBio, ATAI, Forge Biologics and Spark Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
An AI-enabled platform is developed for infectious disease treatment.
domain founded_year HQ Location
Therapeutics for genetic diseases are developed through targeted interventions.
domain founded_year HQ Location
A biopharmaceutical company accelerating innovative mental health treatments.
domain founded_year HQ Location
Gene therapies for rare diseases are developed to treat patients.
domain founded_year HQ Location
Gene therapies for rare diseases including retinal dystrophies are developed.
domain founded_year HQ Location
Provider of cell therapies to treat cancer and hematologic conditions
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Cardiogen Biosciences

Frequently Asked Questions about Cardiogen Biosciences

When was Cardiogen Biosciences founded?

Cardiogen Biosciences was founded in 2014.

Where is Cardiogen Biosciences located?

Cardiogen Biosciences is headquartered in Palo Alto, United States. It is registered at Palo Alto, California, United States.

Is Cardiogen Biosciences a funded company?

Cardiogen Biosciences is a funded company, having raised a total of $525.8K across 1 funding round to date. The company's 1st funding round was a Seed of $525.8K, raised on Nov 06, 2014.

What does Cardiogen Biosciences do?

Cardiogen Biosciences was founded in 2014 and is based in Palo Alto, United States. Focus is placed on the biotechnology sector, where AAV gene therapies are developed to address rare inherited arrhythmogenic diseases. Operations center on advancing treatments without approved options, including a lead product for the CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia (CASQ2-CPVT). Research and development activities are conducted to target these unmet medical needs.

Who are the top competitors of Cardiogen Biosciences?

Cardiogen Biosciences's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.

Who are Cardiogen Biosciences's investors?

Cardiogen Biosciences has 1 investor. Key investors include AudentesTherapeutics.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available